[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Gastric Ulcers pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 42 pages | ID: G1D30AE1B589EN
VPAResearch

US$ 1,599.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
2020 Gastric Ulcers PIPELINE HIGHLIGHTS
Gastric Ulcers is one of the widely researched conditions during 2020 with 6 companies actively focusing on realizing pipeline’s potential. Development of Gastric Ulcers medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Gastric Ulcers market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Gastric Ulcers.

Good progress is anticipated during 2020 and 2021 with Gastric Ulcers pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Gastric Ulcers pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Gastric Ulcers DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Gastric Ulcers pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Gastric Ulcers pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Gastric Ulcers presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Gastric Ulcers pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Gastric Ulcers DRUG PROFILES
Gastric Ulcers development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-
  • Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
  • Phase of development
  • Mechanism of Action
  • Route of Administration
  • Companies involved including originator, licensing companies, developer, investors, and others
  • New molecular entity details
  • Orphan drug designation and other special status provided by regulators
Gastric Ulcers COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Gastric Ulcers drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Gastric Ulcers. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 6 Gastric Ulcers companies including company overview, key snapshot, contact information, and their strategies on accelerating Gastric Ulcers pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Axsome Therapeutics Inc, Daewoong Pharmaceutical Co Ltd, Pharmaking Ltd, RaQualia Pharma Inc, Sam-A Pharm Co Ltd, Xuanzhu Pharma Co Ltd

REASONS TO BUY
  • The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
  • This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
  • Buyers can identify most promising drug candidates for treatment of Gastric Ulcers
  • It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
  • Users can estimate possible delays in the delivery of pipeline or launch of new products
  • Stay ahead of competition through understanding their pipeline progression, strategies and outlook
  • The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
  • Optimize your licensing and technology transfer strategies through identification of prospect partners
1. INTRODUCTION TO GASTRIC ULCERS

1.1 Gastric Ulcers- Disease overview
1.2 Gastric Ulcers- Market Size
1.3 Gastric Ulcers- Companies Involved

2. GASTRIC ULCERS PIPELINE SNAPSHOT- 2020

2.1 Gastric Ulcers Pipeline by Phase
2.2 Gastric Ulcers Pipeline by Mechanism of Action
2.3 Gastric Ulcers Pipeline by Route of Administration
2.4 Gastric Ulcers Pipeline- New Molecular Entities
2.5 Gastric Ulcers Pipeline- Orphan Drug Designation/ Special Designation

3. GASTRIC ULCERS DRUG PROFILES

3.1 Current Status
3.2 Gastric Ulcers Drug Snapshot
3.3 Gastric Ulcers Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Axsome Therapeutics Inc Gastric Ulcers Pipeline Insights and Clinical Trials
4.2 Daewoong Pharmaceutical Co Ltd Gastric Ulcers Pipeline Insights and Clinical Trials
4.3 Pharmaking Ltd Gastric Ulcers Pipeline Insights and Clinical Trials
4.4 RaQualia Pharma Inc Gastric Ulcers Pipeline Insights and Clinical Trials
4.5 Sam-A Pharm Co Ltd Gastric Ulcers Pipeline Insights and Clinical Trials
4.6 Xuanzhu Pharma Co Ltd Gastric Ulcers Pipeline Insights and Clinical Trials

5. GASTRIC ULCERS MARKET NEWS AND UPDATES

6. APPENDIX

6.1 Sources and Methodology
6.2 Contact Information


More Publications